HIV Infections Clinical Trial
Official title:
Family Planning Promotion to Prevent Unplanned Pregnancies in HIV Infected Zambian Couples
Prevention of unplanned pregnancies among HIV infected couples decreases the rate of maternal-child virus transmission and the number of children orphaned when parents die of AIDS. This study will evaluate two programs for reducing the number of unplanned pregnancies among HIV infected couples in Zambia.
Eighty percent of the world's HIV infections are in sub-Saharan Africa. In Lusaka, the
capital of Zambia, 85% of pregnant women are married and 47% are in couples with at least one
HIV infected partner (26% concordant positive, 21% discordant). It will be years before
short-course antivirals are widely implemented, and many children who escape infection will
be left orphaned. There are 360,000 AIDS orphans in Zambia, a country of 9 million people,
and 35,000 HIV infected women deliver each year.
An essential component of any HIV prevention strategy must include the prevention of
unplanned pregnancies among couples with HIV. Promotion of ‘dual method’ contraception
(condoms for HIV/STD prevention plus a longer acting method for pregnancy prevention) is
ideal, but unfortunately not widely promoted. Ultimately, the prevention of unplanned
pregnancy in couples with HIV can reduce pediatric HIV, AIDS orphans, and the family
consequences of parental illness and death.
This study will evaluate two interventions aimed at reducing the incidence of unplanned
pregnancies in HIV infected couples. The first intervention will promote more effective
contraception by placing user-independent methods (IUD and Norplant) first in the educational
message hierarchy (currently, family planning education highlights oral contraceptives) and
employing positive message framing. The second intervention will help couples plan for the
consequences of their illness and death. This will include assisting couples to work together
to prepare a will, choose a guardian, and make a financial plan. By focusing on the cost of
educating existing children and on the need to plan for their future care, couples are
encouraged to reflect on the implications of future childbearing. The interventions will be
compared with a standard family planning program with respect to impact on incident
pregnancy, contraceptive choice and pattern of use, psychosocial and behavioral variables,
and future planning actions. Cost-effectiveness will be determined with methods developed
jointly by experts in the fields of HIV therapy in Africa and contraception.
Participants in this study will be randomized to either the user-independent contraception
intervention, the future planning intervention, the contraception plus planning intervention,
or the standard family planning control. Couples will be followed for 1 to 4 years. Women
will have study visits every 3 months; men will have a study visit every year. The primary
study outcome will be comparison of time to pregnancy across intervention groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |